|
Fludarabine + Cyclophosphamide Clinical Trials
3 actively recruiting trials across 2 locations
▲ +1 trial since August 2026
Also known as: Flu/Cy
Pipeline
Phase 1: 2Phase 1/2: 1
Top Sponsors
- Paolo Caimi, MD1
- Nkarta, Inc.1
- HRYZ Biotech Co.1
Indications
- Cancer2
- Lupus Nephritis1
- Primary Membranous Nephropathy1
- Carcinoma of Vulva1
- Carcinoma of Penis1
Other1 trial
Little Rock, Arkansas1 trial
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
Nkarta Investigational Site
Phase 1/2
Cleveland, Ohio1 trial
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.